Nuvectis Reports Positive NXP200 Glioma Trial Data
The Phase 1b study of NXP200 demonstrated high objective response rates in patients with BRAF V600-mutated gliomas.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient safety over rapid development in new oncology treatments?
Nuvectis Pharma released data from a Phase 1b clinical trial evaluating single-agent NXP200 in 27 patients with recurrent or progressive BRAF V600-mutated gliomas. Results presented at the ESMO Congress showed an 85.2% disease control rate among all evaluable participants.
Why it matters
These results provide early clinical evidence for the efficacy of NXP200 in treating hard-to-reach glioma subtypes. The therapy recently received Breakthrough Therapy Designation in China, marking a significant step toward potential global therapeutic options.
The study reported an objective response rate of 40.0% for high-grade gliomas and 42.9% for low-grade cases. Researchers noted deep tumor reductions exceeding 80% in 87.5% of high-grade and 66.7% of low-grade responders.
The players
Nuvectis Pharma
A biopharmaceutical company based in Fort Lee, New Jersey, that focuses on the development of precision oncology treatments.
Haisco
A pharmaceutical organization that entered into an agreement with Nuvectis to license NXP200 rights.
The details
Responses in the 27-patient trial were assessed using RANO 2.0 criteria, revealing a 14.3% incidence of Grade 3 or higher treatment-related adverse events. Patients with high-grade gliomas showed a median duration of response of 6.97 months and a median overall survival of 17.15 months.
Timeline
April 2026: NXP200 was selected for the Starlight Program in China.
May 4, 2026: Data cutoff date for the Phase 1b clinical study.
June 2026: Nuvectis in-licensed exclusive rights to NXP200.
September 2026: NXP200 received Breakthrough Therapy Designation in China.
October 26, 2026: Clinical trial data was presented at the ESMO Congress.
The Big Picture
This clinical advancement aligns with the development pathways established by the Starlight Program by China's Center for Drug Evaluation. The program creates a prioritized regulatory framework that accelerates the evaluation of innovative oncological therapies for rare or severe conditions.
These trial results offer a potential new treatment pathway for patients facing recurrent or progressive gliomas. Ongoing clinical development may eventually provide doctors with additional options to address these specific genetic tumor mutations.
The takeaway
NXP200 shows promising activity in treating BRAF V600-mutated gliomas with manageable safety profiles. Patients and clinicians should monitor for future updates regarding the planned U.S. IND filing scheduled for late 2026.
What happens next
Nuvectis Pharma intends to file a U.S. Investigational New Drug (IND) application for NXP200 before the conclusion of 2026.
Further reading
For more information on current developments in oncology, visit the Cancer section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient safety over rapid development in new oncology treatments?
